Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 4/20 | 0.62 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.62 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.62 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9524977 | 0.87 | ABCC9 (0.58) | ABCC9ABCC8KCNJ11KCNJ8ABCB1 | |
| SCHEMBL9525765 | 0.86 | ABCC9 (0.46) | ABCC9ABCC8KCNJ11KCNJ8ABCB1 | |
| SCHEMBL8311739 | 0.84 | ABCC9 (0.60) | ABCC9ABCC8KCNJ11KCNJ8OPRD1 | |
| SCHEMBL9527685 | 0.84 | ABCC9 (0.44) | ABCC9ABCC8KCNJ11KCNJ8ABCB1 | |
| SCHEMBL8130002 | 0.83 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11KCNJ8OPRD1 | |
| SCHEMBL9525790 | 0.83 | ABCC9 (0.41) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL9525211 | 0.83 | ABCC9 (0.43) | ABCC9ABCC8KCNJ11KCNJ8ABCB1 | |
| SCHEMBL9527732 | 0.82 | ABCC9 (0.41) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL9527811 | 0.82 | ABCC9 (0.42) | ABCC9ABCC8KCNJ11KCNJ8ABCB1 | |
| SCHEMBL9527792 | 0.82 | ABCC9 (0.42) | ABCC9ABCC8KCNJ11KCNJ8PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0298452-B1 | 2H-1-BENZOPYRANE DERIVATIVES SUBSTITUTED IN POSITION 4 BY ARYL OR N-HETEROARYL | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-30 | — | — | EP | claimed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| US-6037479-A | USEFUL IN ENANTIOSELECTIVE REACTIONS AND WHICH GIVE RISE TO IMPROVED OPTICAL YIELDS | HOFFMAN-LA ROCHE INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1999001453-A1 | A PROCESS FOR THE MANUFACTURE OF OPTICALLY ACTIVE CHROMANYLPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-14 | — | — | WO | disclosed |
| US-5118694-A | Hypotensive agents; treatment for cardiovascular and muscular disorders | HOFFMANN-LA ROCHE INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-4971982-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, SMOOTH MUSCLE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | ABCC9 633/4885ABCC8 1479/4885KCNJ11 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.